- Home
- HXHX vs AGEN Comparison
HXHX vs AGEN Comparison
Compare HXHX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HXHX
- AGEN
- Stock Information
- Founded
- HXHX 2003
- AGEN 1994
- Country
- HXHX China
- AGEN United States
- Employees
- HXHX N/A
- AGEN N/A
- Industry
- HXHX Trucking Freight/Courier Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HXHX Industrials
- AGEN Health Care
- Exchange
- HXHX Nasdaq
- AGEN Nasdaq
- Market Cap
- HXHX 36.9M
- AGEN 38.1M
- IPO Year
- HXHX 2025
- AGEN 2000
- Fundamental
- Price
- HXHX $1.76
- AGEN $2.77
- Analyst Decision
- HXHX
- AGEN Buy
- Analyst Count
- HXHX 0
- AGEN 4
- Target Price
- HXHX N/A
- AGEN $8.00
- AVG Volume (30 Days)
- HXHX 2.3M
- AGEN 712.2K
- Earning Date
- HXHX 01-01-0001
- AGEN 05-06-2025
- Dividend Yield
- HXHX N/A
- AGEN N/A
- EPS Growth
- HXHX N/A
- AGEN N/A
- EPS
- HXHX 0.30
- AGEN N/A
- Revenue
- HXHX $25,712,499.00
- AGEN $103,463,000.00
- Revenue This Year
- HXHX N/A
- AGEN $4.03
- Revenue Next Year
- HXHX N/A
- AGEN $5.57
- P/E Ratio
- HXHX $5.91
- AGEN N/A
- Revenue Growth
- HXHX N/A
- AGEN N/A
- 52 Week Low
- HXHX $1.58
- AGEN $1.38
- 52 Week High
- HXHX $6.29
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- HXHX N/A
- AGEN 71.19
- Support Level
- HXHX N/A
- AGEN $1.60
- Resistance Level
- HXHX N/A
- AGEN $3.40
- Average True Range (ATR)
- HXHX 0.00
- AGEN 0.32
- MACD
- HXHX 0.00
- AGEN 0.18
- Stochastic Oscillator
- HXHX 0.00
- AGEN 71.29
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).